Fig. 5From: A potential immunotherapeutic and prognostic biomarker for multiple tumors including glioma: SHOX2Mutation feature of SHOX2 in different tumors. The alteration frequency with mutation type (A) and mutation site (B) are showed. C Detection of differential somatic mutations in gliomas, including 25% SHOX2low group (C) and 25% SHOX2high group (D)Back to article page